Novartis' BTK inhibitor beats placebo in dermatology trial, lining up another potential indication

Novartis’ BTK inhibitor remibrutinib reduced disease activity in patients with the skin disease hidradenitis suppurativa, potentially setting up another indication for the pharma to tackle with the BTK inhibitor.